InvestorsObserver is giving Immunitybio Inc (IBRX) an Analyst Rating Rank of 36, meaning IBRX is ranked higher by analysts than 36% of stocks. The average price target for IBRX is $4.5 and analyst’s rate the stock as a Buy.
Wall Street analysts are rating IBRX a Buy today. Find out what this means to you and get the rest of the rankings on IBRX!